Cipla inches higher by 1.26% as it reports resilient FY22 results
5paisa Research Team
Last Updated: 11th May 2022 - 05:44 pm
The company witnessed a growth of 12.8% in revenues for FY22
Cipla Ltd, an S&P BSE 100 company primarily engaged in manufacturing pharmaceuticals drugs, has been trending on Dalal Street as it has rallied by about 1.26% amid a falling market from its previous close of Rs 926.25. The scrip opened at Rs 890 and made a day’s high of Rs 942.50.
The company announced its Q4 and FY22 results on 10th May. In Q4FY22, revenue grew by 13.94% YoY to Rs 5223.94 crore from Rs 4584.88 crore in Q4FY21. On a sequential basis, the top line was down by 4.02%. PBIDT (Ex OI) was reported at Rs 749.72 crore, down by 5.84% as compared to the year-ago period and the corresponding margin was reported at 14.25%, contracting by 304 basis points YoY. PAT was reported at Rs 376.72 crore, down by 9.34% from Rs 415.51 crore in the same quarter of the previous fiscal year. The PAT margin stood at 7.16% in Q4FY22 contracting from 9.02% in Q4FY21.
As far as the fiscal 2022 results are concerned, the revenues grew by 12.8% to Rs 21,623 crore as against FY21. The EBITDA and PAT increased by 7% and 6.5% to Rs 4,834 crore and Rs 2,559.5 crore, respectively. The stock witnessed a gap down of 3.88% but eventually recovered during the day.
Cipla Ltd focuses on the development of new formulations and has a wide range of pharmaceutical products. They offer prescription drugs, bulk drugs, animal products, pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. The stock has a 52-week high of Rs 4,986.85 and a 52-week low of Rs 1,926.
Trending on 5paisa
Discover more of what matters to you.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.
Want to Use 5paisa
Trading App?
